Versartis, Inc. (NASDAQ:VSAR) Director Srinivas Akkaraju acquired 513,872 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was purchased at an average cost of $2.21 per share, for a total transaction of $1,135,657.12. Following the completion of the acquisition, the director now owns 14,955 shares in the company, valued at $33,050.55. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Srinivas Akkaraju also recently made the following trade(s):

  • On Friday, December 1st, Srinivas Akkaraju acquired 419,700 shares of Versartis stock. The stock was purchased at an average cost of $2.13 per share, for a total transaction of $893,961.00.

Versartis, Inc. (NASDAQ VSAR) remained flat at $$2.03 on Tuesday. The company’s stock had a trading volume of 906,910 shares, compared to its average volume of 814,075. Versartis, Inc. has a 12 month low of $1.60 and a 12 month high of $24.00. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.11.

Versartis (NASDAQ:VSAR) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.78). During the same period in the prior year, the business earned ($0.92) earnings per share. research analysts anticipate that Versartis, Inc. will post -4.14 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC grew its holdings in shares of Versartis by 1.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 32,597 shares of the biopharmaceutical company’s stock worth $569,000 after purchasing an additional 535 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Versartis by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 109,409 shares of the biopharmaceutical company’s stock worth $1,910,000 after purchasing an additional 627 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Versartis by 4.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,326 shares of the biopharmaceutical company’s stock worth $459,000 after purchasing an additional 1,204 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Versartis by 4.2% during the 2nd quarter. Rhumbline Advisers now owns 35,388 shares of the biopharmaceutical company’s stock worth $618,000 after buying an additional 1,420 shares during the last quarter. Finally, Alps Advisors Inc. lifted its position in shares of Versartis by 6.2% during the 2nd quarter. Alps Advisors Inc. now owns 31,780 shares of the biopharmaceutical company’s stock worth $555,000 after buying an additional 1,845 shares during the last quarter. 49.18% of the stock is currently owned by institutional investors.

A number of research analysts have commented on VSAR shares. ValuEngine lowered Versartis from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Cowen reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Versartis in a report on Wednesday, August 23rd. Zacks Investment Research raised Versartis from a “sell” rating to a “hold” rating in a report on Wednesday, August 30th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Versartis in a report on Friday, September 8th. Finally, Barclays lowered Versartis from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $28.00 to $4.00 in a report on Friday, September 22nd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $7.22.

ILLEGAL ACTIVITY NOTICE: “Insider Buying: Versartis, Inc. (VSAR) Director Buys 513,872 Shares of Stock” was first reported by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/05/insider-buying-versartis-inc-vsar-director-buys-513872-shares-of-stock.html.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.